LE WE PMID CA
Rituximab ttCD202437Rituximab ttCD20

81C6 ttTenascin

Abatacept ttCTLA4Conjugate

Abciximab ttGPIIAIIIB

Adalimumab ttTNFalpha

AIN457

Alefacept

Alemtuzumab ttCD52

AMG386 ttAngiopoietin1 ttAngiopoietin2

Antibodies (therapeutic use)

Arthritis (rheumatoid)

Atacicept ttBlys ttAPRIL

Autoantibodies Anti Factor VIII

BAFF

Bapineuzumab ttAmyloidBeta

Basiliximab ttIL2R

Belatacept ttCD80 ttCD86

Belimumab ttBLyS

Bevacizumab ttVEGF

Biologicals (Adverse effects)

BLYS

Brentuximab vedotin ttCD30

Briakinumab ttIL12 ttIL23

Canakinumab ttIL1beta

Catumaxomab ttEpCAM ttCD3 linkerAb

Certolizumab ttTNFalpha

Cetuximab ttEGFR

Cladribine

Daclizumab ttIL2R

Dalotuzumab ttIGF1R

Denosumab ttRANKL

Devic neuromyelitis optica

Eculizumab ttFactorH

Efalizumab ttLFA1

Epratuzumab ttCD22

Etanercept ttTNFalpha

FactorIXFc ttFactorIX

FactorVIIIFc ttFactorVIII

Farletuzumab ttFolateRalpha

Figitumumab ttIGF1R

Fingolimod

Fumarate

Galiximab ttCD80

Gemtuzumab ozogamicin ttCD33

Girentuximab ttCarbonicAnhydraseIX

Golimumab ttTNFalpha

Ibritumomab tiuxentan yttrium ttCD20

Immunosuppressive agents

Infliximab ttTNFalpha

Inotuzumab ozogamicin ttCD22

Interferon alpha and preliminary (BASKET)

Ipilimumab ttCTLA4

JC Virus

Kidney (FSGS)

Kidney (Minimal change nephrotic syndrome)

Laquinimod

Lymphoma (Follicular)

Mepolizumab ttIL5

Motavizumab ttRSVirus

Multiple sclerosis

MuromonabCD3 ttCD3

Myasthenia gravis

Myopathy (Inflammatory)

Naptumomab estafenatox tt5T4

Natalizumab ttIntegrinalpha4

Necitumumab ttEGFR

Neuropathy peripheral

Nimotuzumab ttEGFR

Obinutuzumab ttCD20

Ocrelizumab ttCD20

Ofatumumab ttCD20

Omalizumab ttCD20

Otelixizumab ttCD3

Pagibaximab ttLipoteichoicAcidStaphlococcus

Palivizumab ttRSVirusFprotein

Panitumomab ttEGFR

Pertuzumab ttHER2

Progressive multifocal leukoencephalopathy

QPI1002 ttp53

Ramucirumab ttVEGFR2

Ranibizumab ttVEGF

Raxibacumab ttAnthrax

REGN88 ttIL6R

Repertaxin ttCXCR1 ttCXCR2

Reslizumab ttIL5

Rilonacept ttIL1R

Rituximab ttCD20

RPSGLIG ttPSelectin

Solanezumab ttAmyloidBeta

Systemic lupus erythematosus

T1H ttCD6

Tanezumab ttNGF

Teplizumab ttCD3

Teriflunomide

Tocilizumab ttIL6

Tositumomab ttCD20

TP10 ttsCR3

Transplantation

Trastuzumab emtansine ttHER2

Trastuzumab ttHER2

Tremelimumab ttCLTA4

Ustekinumab ttIL12 ttIL23

Vasculitis (BASKET)

Vedolizumab ttIntegrina4b7

Zalutumumab ttEGFR

Zanulimumab ttCD4

2007  
1
Targeted therapies in rheumatoid arthritis: Focus on rituximab.
[19707303] Biologics 1(4): 325-33 (2007)
2009  
2
Rituximab for the first-line treatment of stage III/IV follicular non-Hodgkin's lymphoma.
[19567210] Health Technol Assess 13 Suppl 1(-): 23-8 (2009)
2006  
3
A review of rituximab in cutaneous medicine.
[16638371] Dermatol Online J 12(1): 3 (2006)
2009  
4
Expanded use of rituximab in the management of non-Hodgkin lymphoma.
[20616906] Onco Targets Ther 2(-): 189-97 (2009)
2003  
5
An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab.
[12649096] Ann Oncol 14(4): 520-35 (2003)
2008  
6
The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy.
[18779537] Oncologist 13(9): 954-66 (2008)
2008  
7
The effects of rituximab on immunocompetency in patients with autoimmune disease.
[18163518] Arthritis Rheum 58(1): 5-14 (2008)
2007  
8
Monoclonal antibodies for B-cell lymphomas: rituximab and beyond.
[18024635] Hematology Am Soc Hematol Educ Program -(-): 233-42 (2007)
2011  
9
Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis.
[21378402] Ann Rheum Dis 70(6): 909-20 (2011)
2010  
10
Good and bad memories following rituximab therapy.
[20039422] Arthritis Rheum 62(1): 1-5 (2010)
2010  
11
Am"B"valent: anti-CD20 antibodies unravel the dual role of B cells in immunopathogenesis.
[20339090] Blood 116(4): 515-21 (2010)
2009  
12
Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project.
[19264918] Blood 113(20): 4834-40 (2009)
2010  
13
Anti-CD20 monoclonal antibodies: historical and future perspectives.
[19773256] Haematologica 95(1): 135-43 (2010)
2007  
14
Rituximab for the treatment of acquired antibodies to factor VIII.
[17229637] Haematologica 92(1): 66-71 (2007)
2011  
15
New insight in the mechanism of action of rituximab: the interferon signature towards personalized medicine.
[21955850] Discov Med 12(64): 229-36 (2011)
2010  
16
Targeting B cells for the treatment of SLE: the beginning of the end or the end of the beginning?
[21122473] Discov Med 10(54): 416-24 (2010)
2003  
17
Clinical use of rituximab in haematological malignancies.
[14562003] Br J Cancer 89(8): 1389-94 (2003)
2007  
18
Rituximab: a B-cell depletion therapy for dermatologic disease.
[17762903] Skin Therapy Lett 12(6): 6-9 (2007)
2008  
19
Rituximab in minimal change nephropathy and focal segmental glomerulosclerosis: report of four cases and review of the literature.
[19011266] Neth J Med 66(10): 408-15 (2008)
2008  
20
Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies.
[18585457] Curr Opin Immunol 20(4): 444-9 (2008)
2010  
21
2010  
22
Novel B cell therapeutic targets in transplantation and immune-mediated glomerular diseases.
[20007678] Clin J Am Soc Nephrol 5(1): 142-51 (2010)
2010  
23
New approaches in the management of multiple sclerosis.
[21151622] Drug Des Devel Ther 4(-): 343-66 (2010)
2010  
24
Practical considerations on the use of rituximab in autoimmune neurological disorders.
[21179602] Ther Adv Neurol Disord 3(2): 93-105 (2010)
2011  
25
Antibody-based therapeutics to watch in 2011.
[21051951] MAbs 3(1): 76-99 (2011)
2010  
26
Antibody immunosuppressive therapy in solid organ transplant: Part II.
[20948291] MAbs 2(6): 607-12 (2010)
2010  
27
Antibodies to watch in 2010.
[20065640] MAbs 2(1): 84-100 (2010)
2010  
28
Antigenic modulation and rituximab resistance.
[20350659] Semin Hematol 47(2): 124-32 (2010)
2010  
29
Rituximab: mechanism of action.
[20350658] Semin Hematol 47(2): 115-23 (2010)
2009  
30
Rituximab: a review of dermatological applications.
[20729962] J Clin Aesthet Dermatol 2(5): 29-37 (2009)
2010  
31
Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis.
[20298966] Lancet Neurol 9(4): 425-37 (2010)
2010  
32
Review of the safety and feasibility of rapid infusion of rituximab.
[20592783] J Oncol Pract 6(2): 91-3 (2010)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.



  • Rituximab ttCD20

  • The BDOM Bibliographic Dictionary of Medicine is a curated collection of free medical articles tagged to concepts.
    Contents until 2011 are reviews from PubMed, contents flagged 'PMC' are regular articles from PubMed Central.
    Search BDOM
    Nephrology Collection
    Radiology Locator

    PubMedCentral monthly collection of free medical articles by major subject

    The framed wikipedia articles are from en.wikipedia.org and they are the actual versions; the first is from Nephropedia